Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

An immunosuppressed rabbit model of invasive aspergillosis was used to evaluate a novel micellar preparation of cholesterol sulfate complexed to amphotericin B. The acute LD50 of amphotericin B-deoxycholate was 5.1 mg/kg versus 20 mg/kg for the amphotericin/cholesterol-sulfate complexes. Amphotericin B-deoxycholate given iv at a dose of 1.5 mg/kg was more effective in sterilizing liver and kidney than the amphotericin/cholesterol-sulfate complexes given iv at 1.5-4.5 mg/kg, but infection persisted in the lungs of all rabbits treated with those doses. Infection persisted even when the rabbits were given a lethal dose of amphotericin B-deoxycholate (4.5 mg/kg), but a dose of 15 mg/kg of the amphotericin/cholesterol-sulfate complexes sterilized tissues and was associated with no acute lethality. Equivalent doses of the amphotericin/cholesterol-sulfate complexes were less effective than amphotericin B-deoxycholate, but a fourfold decrease in acute lethality improved the therapeutic index of amphotericin B. The amphotericin/cholesterol-sulfate complexes appear to be an improved means of amphotericin B delivery and may improve therapy for invasive aspergillosis.

[1]  J. Ryan,et al.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. , 1988, The Journal of infectious diseases.

[2]  F. Szoka,et al.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B , 1987, Antimicrobial Agents and Chemotherapy.

[3]  L. Liu,et al.  In‐vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice , 1987, The Journal of pharmacy and pharmacology.

[4]  M. Goldberg,et al.  Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.

[5]  V. Andriole,et al.  The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. , 1985, The Journal of infectious diseases.

[6]  J. Reuben,et al.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. , 1985, The Journal of infectious diseases.

[7]  F. Szoka,et al.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice , 1984, Antimicrobial Agents and Chemotherapy.

[8]  C. Kauffman,et al.  Effect of Prophylactic Ketoconazole and Nystatin on Fungal Flora , 1984, Mykosen.

[9]  G. Lopez-Berestein,et al.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B , 1984, Antimicrobial Agents and Chemotherapy.

[10]  J. Graybill,et al.  Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. , 1984, The American review of respiratory disease.

[11]  G. Lopez-Berestein,et al.  Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. , 1984, Cancer drug delivery.

[12]  E. Hersh,et al.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. , 1983, The Journal of infectious diseases.

[13]  E. Hersh,et al.  Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. , 1983, Cancer drug delivery.

[14]  J. Graybill,et al.  Amphotericin B in liposomes: a novel therapy for histoplasmosis. , 1982, The American review of respiratory disease.

[15]  J. Graybill,et al.  Treatment of murine cryptococcosis with liposome-associated amphotericin B. , 1982, The Journal of infectious diseases.

[16]  R. Marier,et al.  A solid-phase radioimmunoassay for the measurement of antibody to Aspergillus in invasive aspergillosis. , 1979, The Journal of infectious diseases.

[17]  J. Aisner,et al.  Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. , 1977, Annals of internal medicine.

[18]  L. Young,et al.  Aspergillosis complicating neoplastic disease. , 1973, The American journal of medicine.

[19]  V. Devita,et al.  Aspergillosis. The spectrum of the disease in 98 patients. , 1970, Medicine.

[20]  E J Freireich,et al.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.

[21]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .